Home
»
Press Room
»
Influenza Vaccine Market To Reach $14,797.35Mn By 2033

Influenza Vaccine Market To Reach $14,797.35 Million By 2033

April 2026 | Report Format: Electronic (PDF)

Influenza Vaccine Market Growth & Trends

The global influenza vaccine market size is estimated to reach USD 14,797.35 million by 2033, registering a CAGR of 6.51% from 2026 to 2033, according to a new report by Grand View Research, Inc. The increase in immunization programs, rising awareness regarding flu and influenza, and surge in R&D activities pertaining to flu vaccines are anticipated to propel market growth. In addition, the inclusion of the influenza vaccine in various national immunization programs and increasing awareness programs for immunizations across the globe is anticipated to boost the market growth.

The ongoing influenza vaccination national schemes globally are anticipated to propel the market. For instance, programs such as Universal Influenza Immunization Program and NIP Vaccination Programs among others are some of the key immunization programs. These offer flu vaccines free of cost to all the target population. The key objective of such programs is to eliminate the risk of flu-like disorders.

Trivalent and Quadrivalent vaccines are commercially available influenza vaccines. Among these, the quadrivalent vaccines are the most preferred type owing to their high efficacy and their ability to combat two influenza-B viruses and two influenza-A viruses. Leading companies are undertaking efforts to conduct research studies for quadrivalent product development. For instance, in November 2022, Pfizer Inc. and BioNTech SE announced the advancement of an mRNA-based combination vaccine candidate for COVID-19 and influenza to mitigate two life-threatening respiratory conditions.

Moreover, due to the emergence of new strains, scientists are devising a vaccination strategy that could prevent the flu virus with multiple strains and achieve long-lasting immunity in an individual. For instance, in March 2022, scientists from Monash University, Melbourne, and the National University of Singapore published research in the ‘Proceedings of the National Academy of Sciences’. This research featured a platform to efficiently offer vaccine candidate M2e to the immune cells to attain long-lasting immunity against different virus strains.

Furthermore, various initiatives undertaken by leading market participants are likely to provide exponential growth opportunities for the market. For instance, in February 2020, Abbott announced the launch of inactivated quadrivalent vaccine for protection against four virus strains in India. In addition, in January 2021, ModernaTX, Inc. announced the company’s plans to use mRNA technology to manufacture and develop Nipah, HIV, and flu virus vaccines.

key Request a free sample copy or view report summary: Influenza Vaccine Market Report

Influenza Vaccine Market Report Highlights

Based on vaccine type, the inactivated vaccines segment accounting for 92.11% of the revenue share in 2025, attributed to the high global burden of influenza, strong demand for proven and safe immunization solutions, and the widespread presence of established manufacturers offering large-scale production capabilities.
Based on indication, the quadrivalent segment accounting for 87.46% of the total share in 2025, attributed to its broader protection against four influenza strains, two influenza A and two influenza B lineages, making it highly effective in reducing infection risk across diverse populations.
Based on age group, the adult segment held the largest revenue share of 78.10% in 2025, driven by strong immunization initiatives and high procurement volumes by global organizations such as UNICEF, GAVI, and PAHO.
Based on route of administration, the injection segment accounting for 91.92% of the total revenue share in 2025, driven by the widespread use of intramuscular vaccine formulations in national immunization programs.
Based on distribution channel, the hospitals & pharmacy held the largest revenue share of 53.68% in 2025, driven by their central role in vaccine storage, administration, and accessibility.
North America influenza vaccine market dominated the global industry, accounting for a 52.66% revenue share, supported by high vaccination coverage, advanced healthcare infrastructure, and strong government-backed immunization programs.

Influenza Vaccine Market Segmentation

Grand View Research has segmented the global influenza vaccine market based on vaccine type, indication, age group, route of administration, distribution channel, and region:

Influenza Vaccine Vaccine Type Outlook (USD Million, 2021 - 2033)